About 37 million people were living with HIV in 2017, but nearly half were not on treatment. **Global targets to end the AIDS epidemic by 2030** would mean providing 16 million more people with access to treatment. By 2020, **90%** of all people living with HIV should know their status, **90%** of those who know they are living with HIV should be on treatment, **90%** of all people receiving treatment should achieve viral suppression.

**WHAT WE DO**
Unitaid is helping reach 2020 targets by investing in innovations to prevent, diagnose and treat HIV more quickly, affordably and effectively.

**HOW WE DO IT**
1. Unitaid identifies health solutions with the most potential to reduce the global burden of HIV.
2. Unitaid provides targeted, time-limited grants designed to bring health innovations to millions of people in low- and lower-middle-income countries.
3. Unitaid’s work sets the stage for governments and partners to scale up innovations, working toward worldwide elimination of HIV.

**OUR ACHIEVEMENTS**
Our HIV projects, which make up the largest segment of our grant portfolio, slashed the price of antiretroviral (ARV) drugs for children and second-line ARV treatment for adults, and brought advanced point-of-care diagnostics to babies who live far from large health facilities, among other achievements.

**OUR ACTIVE GRANT PORTFOLIO**

**PREVENTION**
People at high risk of HIV can take ARVs to protect themselves from getting infected. Unitaid is investing US$ 41 million in this form of prevention called pre-exposure prophylaxis or “PrEP”. We are partnering with Fiotec to offer PrEP to high-risk groups in Brazil, Mexico and Peru, and we are also collaborating with Wits RHI and the South African Department of Health to make PrEP and other services available to young women in South Africa. Figures include investments in WHO enabling grants that support our HIV self-testing and PrEP portfolio and provide technical support to focus countries, including countries in Asia.
**Testing and Monitoring**

One in four people living with HIV do not know they have the virus. Unitaid-funded projects support quick, convenient diagnostics that are affordable and encourage more people to get tested.

Unitaid has also invested US$ 150 million to improve technologies for testing viral load. A high viral load suggests a patient is taking their medicine incorrectly or needs to change treatment. Among our projects:

- **US$ 97.4 Million**
  Unitaid is investing to create a market for HIV self-testing in Africa.

- **US$ 63 Million**
  Our project with EGPAF is linking babies exposed to HIV in Africa to fast, point-of-care testing.

- **US$ 95 Million**
  Our collaboration with CHAI and UNICEF is expanding new technologies for early-infant diagnosis and viral load testing.

**Treatment**

Nearly half of children living with HIV are not getting any treatment. For those who are, paediatric HIV drugs taste bad, are hard to administer, need refrigeration, and are unsuitable for those co-infected with HIV and TB. Our response includes:

- **US$ 17.3 Million**
  To develop better HIV drugs for children in collaboration with Drugs for Neglected Diseases initiative (DNDi).

- **US$ 67 Million**
  Invested across four projects to bring the best HIV drugs to Africa.
  The projects are evaluating dolutegravir-based regimens in pregnancy and for TB coinfection. A dolutegravir + darunavir combination is being introduced for second-line HIV therapy.

- **US$ 34 Million**
  To widen access to the best-available HIV drugs through a grant to CHAI. Working with governments and industry, the project aims to cut production costs, while generating demand and adoption of adult and children’s medicines.

The main contributors to Unitaid are: France, United Kingdom, Brazil, Norway, Chile, South Korea, Mauritius, Madagascar, Spain and Bill & Melinda Gates Foundation.

Unitaid is a hosted partnership of the World Health Organization.

[www.unitaid.org](http://www.unitaid.org)